General

Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. Howell D et al. Br J Haematol. 2017 Feb 1. doi: 10.1111/bjh.14513. [Epub ahead of print]. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. Lisenko K et al. BMC Cancer. 2017 Feb 22;17(1):151. doi: 10.1186/s12885-017-3137-4. Association between response rates…

Supportive treatments

Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Palmaro A et al. Pharmacoepidemiol Drug Saf. 2017 Feb 15. doi: 10.1002/pds.4180. [Epub ahead of print]. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Cho YK et al. Clin Pharmacol Ther. 2017 Feb 4. doi: 10.1002/cpt.644. [Epub…

Complications of myeloma and its treatments

Renal failure in multiple myeloma: something new on the horizon. Offidani M et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14548. [Epub ahead of print]. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients. Vázquez L et al. Rev Esp Quimioter. 2017 Feb 14. pii: vazquez14feb2017. [Epub ahead of print]. Myelosuppression-sparing treatment of central nervous…

Current treatments

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Berdeja JG et al. Br J Haematol. 2017 Feb 7. doi: 10.1111/bjh.14536. [Epub ahead of print]. Impact of induction treatment before autologous stem cell transplantation on long term outcome in patients with newly diagnosed multiple…

Diagnostic techniques and prognostic indicators

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. González-Calle V et al. Haematologica. 2017 Jan 25. pii: haematol.2016.158345. doi: 10.3324/haematol.2016.158345. [Epub ahead of print]. Capillary electrophoresis analysis of N-glycosylation changes of serum paraproteins in multiple myeloma. Kovacs Z et al. Electrophoresis. 2017 Jan 24. doi: 10.1002/elps.201700006. [Epub ahead…

Related conditions

New and developing therapies for AL amyloidosis. Zumbo G et al. Expert Opin Pharmacother. 2016 Dec 29:1-11. doi: 10.1080/14656566.2016.1274971. [Epub ahead of print]. Pathological characteristics of fifty patients with renal amyloidosis in Sri Lanka Dasanayaka DL et al. Ceylon Med J. 2016 Dec 30;61(4):189-190. doi: 10.4038/cmj.v61i4.8388. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and…

Emerging treatments

Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Vogl DT et al. Clin Cancer Res. 2017 Jan 4. pii: clincanres.2526.2016. doi: 10.1158/1078-0432.CCR-16-2526. [Epub ahead of print]. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137). Simões-Pires CA et al. Expert Opin Ther Pat. 2017 Jan 16. doi: 10.1080/13543776.2017.1282945.…

Biology and genetics

Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. Durusu İZ et al. Leuk Res. 2017 Jan 16;55:33-40. doi: 10.1016/j.leukres.2017.01.019. [Epub ahead of print]. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Adamik J et al. Mol Cancer Res. 2017 Jan 23. pii: molcanres.0242.2016. doi: 10.1158/1541-7786.MCR-16-0242-T. [Epub ahead of print].…

General

Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Kapoor P et al. Nat Rev Clin Oncol. 2017 Feb;14(2):73-74. doi: 10.1038/nrclinonc.2016.221. Epub 2017 Jan 10. Trends in overall survival and costs of multiple myeloma, 2000-2014. Fonseca R et al. Leukemia. 2017 Jan 20. doi: 10.1038/leu.2016.380. [Epub ahead of print]. Current treatment options of T cell-associated immunotherapy in multiple myeloma. Liu H et…

Supportive treatments

Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M et al. Expert Rev Hematol. 2017 Jan 17. doi: 10.1080/17474086.2017.1283213. [Epub ahead of print].

Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma.
Audat ZA et al. Scoliosis Spinal Disord. 2016 Dec 29;11:47. doi: 10.1186/s13013-016-0107-6. eCollection 2016.